Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Expands By 14.4%

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 952,300 shares, an increase of 14.4% from the December 15th total of 832,200 shares. Based on an average trading volume of 94,200 shares, the days-to-cover ratio is presently 10.1 days. Approximately 4.4% of the shares of the company are short sold.

Gyre Therapeutics Stock Performance

GYRE traded up $0.15 during trading on Friday, reaching $10.95. 48,956 shares of the company’s stock were exchanged, compared to its average volume of 116,811. Gyre Therapeutics has a 1 year low of $8.26 and a 1 year high of $26.37. The company’s fifty day simple moving average is $11.57 and its 200-day simple moving average is $12.64.

Insiders Place Their Bets

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the transaction, the president now directly owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 16,054 shares of company stock valued at $185,897. 19.52% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC acquired a new stake in Gyre Therapeutics during the 3rd quarter worth about $47,000. Barclays PLC boosted its position in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Rhumbline Advisers purchased a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $123,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp purchased a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $218,000. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.